Table 1 Patient data, psoriasis diagnosis, type of TNFα antagonist, interval between last TNFα antagonist and onset/exacerbation of psoriasis.

Case	RF	Anti‐CCP	TNFα antagonists*	Latency‡ (months)	Psoriasis type	Histology	New onset	Family§
1	+	+	ADA†, ETA, INF, ETA	14	Vulgaris	Yes	Yes	No
2	+	+	ETA†	1	Pustulosa	Yes	Exacerbation	No
3	+	+	ETA, ADA†	(4 days)	Vulgaris	Yes	Yes	No
4	+	NA	INF†	2	Vulgaris	No	Exacerbation	Sister
5	+	+	ADA†	5	Pustulosa	Yes	Yes	Brother
6	Neg.	NA	ETA, INF†, ETA, ADA	8	Pustulosa	No	Exacerbation	No
7	+	NA	ETA†	1	Vulgaris	No	Exacerbation	No
8	+	NA	ETA†	2	Vulgaris	No	Yes	No
9	+	NA	ADA†, INF	11	Vulgaris	No	Yes	No

*In order of administration; †TNFα antagonist with onset or exacerbation of psoriasis; ‡latency: interval between first administration of the last TNFα antagonist and onset/exacerbation of psoriasis; §family member with psoriasis.

RF, rheumatoid factor, anti‐CCP, anti‐cyclic citrullinated peptide antibodies; ADA, adalimumab; ETA, etanercept; INF, infliximab.